Charles Alpers, MD
Nelson Fausto-Ann De Lancey Professor
Department of Laboratory Medicine and
Pathology University of Washington

Objectives: Upon completion of this program, attendees should be able to:
1) Understand the structural changes of diabetic nephropathy
2) Understand the potential and barriers for regression of diabetic nephropathy
3) Understand how new therapeutics for diabetes may have benefits in regression of kidney pathology resulting from diabetes

Speaker Disclosures:  Dr. Charles Alpers discloses financial relationships with Boehringer-Ingelheim (Grant/Research support) and Travere (Advisory Committees or Review Panels).

Why Attend? 

Diabetic nephropathy is the leading cause of end-stage renal disease in the Western world, and is of growing importance globally. Until the past several years, no therapeutics existed that could induce regression of diabetic nephropathy; standard therapeutic regimens only slowed the course of progressive disease. We developed a leptin deficient murine model of diabetic nephropathy that could be reversed with leptin replacement. We will discuss how this model provides insights into how new therapeutic regimens recently introduced into clinical practice might have similar beneficial effects and how the model serves as a platform for pre-clinical testing of the benefits of new interventions still in development.

Meeting ID: 953 8092 2494
Passcode: 398691

Grant Acknowledgment:  None

Planning Committee Disclosure:

Drs. Maria Tretiakova, Haodong Xu, Robert Ricciotti & Eleanor Chen disclose no financial or other relationships with any commercial interest in the past 12 months.

Dr. Lawrence True reports the following: Founder/stockholder of LightSpeed Microscopy, Inc.

You must sign-in on the following form to receive CME credit. Sign-in online: https://forms.gle/W2oE8d3MYbnyTDe58

The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 

The University of Washington School of Medicine designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. (Each session is 1.0 credit)